Literature DB >> 30726922

Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice.

Gianmaria Baldin1, Arturo Ciccullo1, Alberto Borghetti2, Simona Di Giambenedetto1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30726922     DOI： 10.1093/jac/dkz009

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  9 in total

Review 1.  Simplifying ARV Therapy in the Setting of Resistance.

Authors:  Neha Sheth Pandit; Daniel B Chastain; Andrea M Pallotta; Melissa E Badowski; Emily C Huesgen; Sarah M Michienzi
Journal:  Curr Infect Dis Rep       Date:  2019-09-07       Impact factor: 3.725

Review 2.  Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.

Authors:  Valeria Cento; Carlo Federico Perno
Journal:  Diagnostics (Basel)       Date:  2021-04-29

3.  Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.

Authors:  Y S Punekar; D Parks; M Joshi; S Kaur; L Evitt; V Chounta; M Radford; D Jha; S Ferrante; S Sharma; J Van Wyk; A de Ruiter
Journal:  HIV Med       Date:  2021-02-02       Impact factor: 3.180

4.  Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort.

Authors:  Tongai G Maponga; Anna L McNaughton; Marije van Schalkwyk; Susan Hugo; Chikezie Nwankwo; Jantjie Taljaard; Jolynne Mokaya; David A Smith; Cloete van Vuuren; Dominique Goedhals; Shiraaz Gabriel; Monique I Andersson; Wolfgang Preiser; Christo van Rensburg; Philippa C Matthews
Journal:  J Infect       Date:  2020-05-01       Impact factor: 6.072

5.  DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.

Authors:  Carmen Hidalgo-Tenorio; Luis López Cortés; Alicia Gutiérrez; Jesús Santos; Mohamed Omar; Carmen Gálvez; Sergio Sequera; Samantha Eisabeth De Jesús; Franciso Téllez; Elisa Fernández; Coral García; Juan Pasquau
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.889

6.  Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).

Authors:  Rosa De Miguel; David Rial-Crestelo; Lourdes Dominguez-Dominguez; Rocío Montejano; Andrés Esteban-Cantos; Paula Aranguren-Rivas; Natalia Stella-Ascariz; Otilia Bisbal; Laura Bermejo-Plaza; Mónica Garcia-Alvarez; Belén Alejos; Asunción Hernando; Mireia Santacreu-Guerrero; Julen Cadiñanos; Mario Mayoral; Juan Miguel Castro; Victoria Moreno; Luz Martin-Carbonero; Rafael Delgado; Rafael Rubio; Federico Pulido; José Ramón Arribas
Journal:  EBioMedicine       Date:  2020-05-11       Impact factor: 8.143

7.  Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.

Authors:  Franco Maggiolo; Roberto Gulminetti; Layla Pagnucco; Margherita Digaetano; Adriana Cervo; Daniela Valenti; Annapaola Callegaro; Cristina Mussini
Journal:  BMC Infect Dis       Date:  2022-10-12       Impact factor: 3.667

Review 8.  Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2020-01       Impact factor: 11.431

9.  DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).

Authors:  Carmen Hidalgo-Tenorio; Juan Pasquau; David Vinuesa; Sergio Ferra; Alberto Terrón; Isabel SanJoaquín; Antoni Payeras; Onofre Juan Martínez; Miguel Ángel López-Ruz; Mohamed Omar; Javier de la Torre-Lima; Ana López-Lirola; Jesús Palomares; José Ramón Blanco; Marta Montero; Coral García-Vallecillos
Journal:  Viruses       Date:  2022-03-04       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.